# ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2 EPIDEMIOLOGY AND TREATMENT OF RENAL CELL CARCINOMA:

EW RENAISSANCE international scientific journal

## **IDENTIFYING KEY RISK FACTORS**

#### Mansurov Sardor Vali o'g'li

Asian International University, Bukhara, Uzbekistan.

#### https://doi.org/10.5281/zenodo.14909826

Renal cell carcinoma makes up about 90% of all kidney cancers and affects thousands of people worldwide every year. This complex cancer shows different patterns when you look at various populations. Healthcare professionals need to identify risk factors early to detect and treat the disease effectively. The rising global kidney cancer rates, especially in developed countries, make understanding these risk factors more significant than ever.

Doctors need a complete approach to treat renal cell carcinoma. They must think over many aspects like tumor size, stage, and the patient's specific condition. Treatment options range from surgical procedures like radical nephrectomy to advanced therapies such as PD-1 inhibitors. This piece gets into the spread, risk factors, and treatment plans for renal cell carcinoma to give healthcare professionals vital information for the best patient care possible.

Understanding Renal Cell Carcinoma

Kidney cancer shows up as either primary or secondary tumors. Renal cell carcinoma (RCC) makes up 80-85% of primary renal neoplasms. These cancers start in the renal tubular epithelium and show various clinical and pathological features.

Definition and type

RCC includes several distinct subtypes that have unique molecular and histological features. Clear cell renal cell carcinoma (ccRCC) is the most important form and accounts for 75% of cases. The other variants are:

RCC Subtype	Prevalence	Characteristics
Papillary RCC	10-15%	Finger-like projections
Chromophobe RCC	5%	Large cells with pale cytoplasm
Collecting duct carcinoma	<1%	Aggressive variant
Unclassified RCC	3-5%	Mixed characteristics
Pathophysiology		

Clear cell RCC develops in the proximal renal tubular epithelium, specifically originating from the proximal tubules. Complex cellular mechanisms drive the disease's pathogenesis and affect hypoxia-inducible factors' regulation, which leads to downstream effects on tumor development.

Genetic factors

# NEW RENAISSANCE international scientific journal ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

Genetic alterations are the foundations of RCC development, and scientists have identified both hereditary and sporadic forms. More than 50% of patients diagnosed with ccRCC show Von Hippel-Lindau (VHL) gene mutations. These mutations cause hypoxia-inducible factors (HIF) to accumulate and help tumors survive through various growth factors. The disease progression also stems from mutations in genes like PBRM-1, SETD2, and BAP-1.

Clinical presentation

RCC stays silent during early stages, and only 25-30% of patients show symptoms when diagnosed. The classic symptoms form a triad:

Flank pain (40% of cases)

Hematuria (40% of cases)

Palpable abdominal mass (25% of cases)

Patients commonly experience paraneoplastic syndromes that affect multiple body systems. These conditions manifest as hypercalcemia in 5% of cases, fever in 20%, and hypertension in 20%. Patients might also experience weight loss (33%) and malaise, which makes early diagnosis difficult. The condition's varied symptoms demand thorough clinical evaluation and proper imaging studies to confirm diagnosis.

Epidemiological Trends in Renal Cell Carcinoma

Renal cell carcinoma's global burden keeps rising, and doctors diagnosed about 403,000 new cases worldwide in 2018. This most important health issue shows unique patterns in various regions and populations. Medical experts need to examine these epidemiological trends carefully.

Global and regional statistics

North America leads with the highest disease burden showing an age-standardized rate (ASR) of 10.9 per 100,000. Western Europe ranks second with 9.7, while Australia/New Zealand follows closely at 9.6. Regional differences become dramatic when you look at Belarus, which tops the national incidence rate at 16.8 per 100,000. The disease affects men and women differently, as men face a 1.7 times higher relative risk.

Temporal trends

RCC incidence continues to show a steady upward trend. United States data reveals cases doubled from 7.1 per 100,000 in 1975 to 14.9 per 100,000 in 2016. Brazil and Ecuador will experience the most important increase across both male and female populations by 2030 according to current projections.

Socioeconomic factors

Socioeconomic status (SES) substantially impacts RCC diagnosis and outcomes. Studies reveal:

Patients with lower SES typically present with later-stage tumors

1142

People without insurance are 1.9 times more likely to present with stage 3 or 4 disease compared to those with private insurance

SSANCE international scientific journal

ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

Patients with Medicaid insurance show 1.3 times higher likelihood of advanced-stage RCC presentation versus privately insured patients

Survival rates

Five-year relative survival rates change based on when doctors find the cancer:

StageSurvival RateStage 193%Stage 2/372.5%Stage 412%

EW RENA

Patient survival rates have gotten better, and now 78.1% of patients live at least 5 years after diagnosis. Still, survival rates differ among various population groups. Doctors find cancer that has spread in about one-third of cases. After surgery, 20-50% of patients see their cancer spread to other parts of the body.

The American Cancer Society's latest numbers show 81,610 new cases expected in 2024, with 52,380 men and 29,230 women affected. They predict 14,390 deaths from kidney cancer that year. Most people get their diagnosis at 65, and the disease mainly affects those between 55 and 74. More people get kidney cancer now, but death rates keep dropping in developed countries because doctors find it earlier and treatments work better.

Identifying and Managing Risk Factors

Medical professionals need to understand risk factors linked to renal cell carcinoma (RCC). This knowledge plays a vital part in preventing and detecting the disease early. Research shows these risk factors affect how RCC develops and progresses by a lot.

Lifestyle-related risk factors

Smoking is one of the most important modifiable risk factors for RCC. Research shows that current smokers face a 38% higher risk than people who never smoked. The danger grows with increased exposure to tobacco. People who smoke 1-9 cigarettes daily have a 31% higher risk, which jumps dramatically to 106% for those who smoke  $\geq$ 40 cigarettes each day.

Obesity stands as another most important modifiable risk factor. Scientists have found a direct relationship between weight and RCC risk. Each BMI unit increase leads to a 7% higher chance of developing RCC. People with morbid obesity (BMI  $\geq$ 35 kg/m<sup>2</sup>) have a 71% higher risk when compared to those maintaining normal weight.

**Risk Increase** 

1143

Medical conditions associated with RCC

Several medical conditions substantially increase RCC risk:

Condition

Hypertension Acquired Cystic Kidney Disease Chronic Kidney Disease 2-3x higher risk

Up to 50x higher risk Substantial increase

Hypertension shows a direct relationship with RCC risk based on dosage levels. People with systolic pressure readings of 150-169 mmHg face double the risk compared to those with readings below 130 mmHg. This increased risk exists regardless of antihypertensive medication use.

Occupational hazards

Workplace exposures add by a lot to RCC risk. Research has revealed several job-related

risk factors:

Chemical exposures:

Trichloroethylene exposure shows a strong link

Cadmium exposure increases risk by 40% in men and 150% in women

Lead exposure raises risk by 50% in men and 160% in women

Workers face additional risks from industrial exposures to specific dusts. Glass fibers and mineral wool fibers have shown clear connections to RCC development. People who work with these materials have a 110% and 150% higher risk respectively.

Prevention strategies

You can reduce your RCC risk by making lifestyle changes and managing certain risk factors:

Smoking cessation: Studies show quitting smoking for over 10 years can reduce your RCC risk by a lot

Weight management:

Keep your BMI under 25 kg/m $^2$ 

Exercise at least 30 minutes daily

Eat plenty of fruits and vegetables

Blood pressure control:

Check your blood pressure regularly

Take medications as prescribed

Cut down on salt intake

Occupational safety:

Use proper protective gear

Stay away from known carcinogens

Make sure your workplace conducts safety checks regularly



These prevention methods work well to lower your risk. Research shows you could cut your RCC risk by half just by quitting tobacco and maintaining a healthy weight. Workplace safety measures and health monitoring are crucial if you work around hazardous materials.

EW RENAISSANCE international scientific journal

ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

Current Treatment Landscape for Renal Cell Carcinoma

Renal cell carcinoma's treatment options have evolved by a lot over time. Modern approaches now combine multiple treatment methods based on each patient's unique needs and disease characteristics. Treatment strategies include surgical procedures, systemic therapies, radiation treatments and integrated care approaches.

Surgical management

Surgery serves as the life-blood of treatment for localized renal cell carcinoma. Treatment options vary based on tumor characteristics and patient factors. Radical nephrectomy stands as the standard approach for tumors larger than 7 cm. Partial nephrectomy has proven to be the preferred option for smaller, localized tumors.

Doctors select the surgical approach based on several factors:

Surgical ApproachPrimary IndicationsKey ConsiderationsRadical Nephrectomy Tumors >7cm, Multiple tumorsComplete kidney removal

Partial Nephrectomy Tumors <4cm, Single tumor Preserves kidney function

Laparoscopic Surgery Selected cases Shorter recovery time

Patients with metastatic disease might benefit from cytoreductive surgery combined with systemic therapy. Selected cases have shown improved survival outcomes.

Systemic therapies

New systemic therapy options have transformed advanced RCC treatment through two key approaches:

Immunotherapy: Checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, and avelumab have showed most important benefits. These treatments boost the body's immune response to fight cancer cells.

Targeted Therapy: Agents that focus on specific molecular pathways, including:

Antiangiogenic therapies that cut off tumor blood supply

mTOR inhibitors that stop cancer cell growth

Treatment approaches that combine immunotherapy and targeted agents have produced better outcomes. Studies report 90% survival rates at 13 months when patients receive pembrolizumab-axitinib combination therapy.

Radiation therapy

Radiation therapy plays multiple essential roles in RCC management, especially when you have patients who cannot undergo surgery or those with metastatic disease. Modern highprecision radiation delivery methods demonstrate promising results:

-Image-guided radiation therapy (IGRT) allows doctors to target tumors with precision

EW RENAISSANCE international scientific journal

ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

-Stereotactic body radiation therapy (SBRT) delivers concentrated radiation doses across 3-5 sessions

Recent studies show radiation therapy's local control rates match surgical outcomes in specific cases, particularly with small, localized tumors. Patients with metastatic disease experience excellent symptomatic improvements through this treatment, which proves most effective for skeletal and brain deposits.

Multidisciplinary approach

RCC management's complexity requires a coordinated team effort. The healthcare team has these key members:

Team Member	Main Role
Urologic Surgeon	Surgical planning and execution
Medical Oncologist	Systemic therapy management
Radiation Oncologist	Radiation treatment planning
Pathologist	Tissue analysis and staging
Radiologist	Imaging interpretation

Studies show this unified approach leads to better patient outcomes with improved survival rates and fewer complications. Team members work together to build personalized treatment plans that think about several key factors:

- Tumor characteristics and stage

- Patient's health conditions and priorities

- Treatment options and their timing

- Quality of life impact

Recent treatment combinations have led to better outcomes and studies show major improvements in progression-free survival. Targeted therapies combined with immune checkpoint inhibitors show especially promising results. These combinations help patients with advanced cases live beyond three years.

Conclusion

Renal cell carcinoma poses a tough medical challenge as its global rates continue to rise. Research shows clear links between RCC and factors we can control, like smoking, obesity, and workplace exposure to harmful substances. This means we can prevent many cases by changing

1146

lifestyles and making workplaces safer. Recent data shows RCC rates vary a lot between different regions and groups of people. Medical teams need targeted screening programs to catch cases early.

Treatment methods have improved patient outcomes by a lot through better care protocols and new therapy options. Doctors now combine surgery with targeted therapies and immunotherapy to get promising results for patients at every stage. Medical breakthroughs help more patients survive, especially when doctors create tailored treatment plans based on each patient's unique characteristics and tumor profiles. A team of different specialists working together delivers the best care possible.

## REFERENCES

- 1. Vali o'g'li, M. S. KIDNEY CANCER: EPIDEMIOLOGY AND TREATMENT.
- Valiyevich, M. S. (2024). Specific Morphofunctional Characteristics of the Kidney Caused by Brain Damage in Various Emergency Situations. Research Journal of Trauma and Disability Studies, 3(4), 286-289.
- 3. PROSTATE CANCER: PATHOLOGY AND TREATMENT. (2024). International Bulletin of Medical Sciences and Clinical Research, 4(11), 65-70. https://doi.org/10.37547/
- 4. MUSHAKLARNING TARAQQIYOTI. MUSHAKLARNING YORDAMCHI APPARATI. *TADQIQOTLAR. UZ*, 40(3), 94-100.
- 5. Abdurashitovich, Z. F. (2024). APPLICATION OF MYOCARDIAL CYTOPROTECTORS IN ISCHEMIC HEART DISEASES. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *39*(5), 152-159.
- Abdurashitovich, Z. F. (2024). SIGNIFICANCE OF BIOMARKERS IN METABOLIC SYNDROME. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 4(9), 409-413.
- Zikrillaev, F. A. (2024). Cardiorehabilitations from Physiotherapeutic Treatments in Cardiovascular Diseases. *American Journal of Bioscience and Clinical Integrity*, 1(10), 96-102.
- 8. Abdurashitovich, Z. F. (2024). Cardiovascular System. Heart. Aorta. Carotid Artery.
- 9. Abdurashitovich, Z. F. (2024). MORPHO-FUNCTIONAL ASPECTS OF THE DEEP VEINS OF THE HUMAN BRAIN. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(6), 203-206.

NEW RENAISSANCE international scientific journal

- MUHIM AHAMIYATLARI VA SOG'LOM TURMUSH TARZIGA TA'SIRI. Лучшие интеллектуальные исследования, 14(4), 111-119.
- 11. Abdurashitovich, Z. F. (2024). ODAM ANATOMIYASI FANIDAN<br/>SINDESMOLOGIYA BO'LIMI HAQIDA UMUMIY<br/>MALUMOTLAR. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В<br/>МИРЕ, 41(4), 37-45.
- 12. Abdurashitovich, Z. F. (2024). THE IMPORTANCE OF THE ASTRAGAL PLANT IN MEDICINE AND ITS EFFECT ON A HEALTHY LIFESTYLE. *ОБРАЗОВАНИЕ* НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 41(4), 88-95.
- 13. Abdurashitovich, Z. F. (2024). Department of Syndesmology from the Science of Human Anatomy General Information About. *Research Journal of Trauma and Disability Studies*, 3(3), 158-165.
- Abdurashitovich, Z. F. (2024). THE COMPLEXITY OF THE FUSION OF THE BONES OF THE FOOT. JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH, 3(5), 223-230.
- 15. Abdurashitovich, Z. F. (2024). ANATOMICAL COMPLEXITIES OF JOINT BONES OF THE HAND. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 4(4), 198-206.
- 16. Зикриллаев, Ф. А. (2024). АНАТОМИЧЕСКОЕ СТРОЕНИЕ ОРГАНОВ ДЫХАНИЯ И ЕГО ЛИЧНЫЕ ХАРАКТЕРИСТИКИ. *ТАDQIQOTLAR. UZ*, 40(3), 86-93.
- 17. Abdurashitovich, Z. F., & Komoliddinovich, S. J. (2024). DIGESTIVE SYSTEM. ANATOMY OF THE STOMACH. *TADQIQOTLAR*. UZ, 40(3), 78-85.
- 18. Abdurashitovich, Z. F. (2024). UMURTQA POG'ONASI BIRLASHUVLARI. *TADQIQOTLAR*. UZ, 40(3), 40-47.
- 19. Rakhmatova, D. B., & Zikrillaev, F. A. (2022). DETERMINE THE VALUE OF RISK FACTORS FOR MYOCARDIAL INFARCTION. FAN, TA'LIM, MADANIYAT VA INNOVATSIYA JURNALI/ JOURNAL OF SCIENCE, EDUCATION, CULTURE AND INNOVATION, 1(4), 23-28.
- 20. Abdurashitovich, Z. F. (2024). MIOKARD INFARKTI UCHUN XAVF OMILLARINING AHAMIYATINI ANIQLASH. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ* ИДЕИ В МИРЕ, 36(5), 83-89.

- 21. Abdurashitovich, Z. F. (2024). THE RELATIONSHIP OF STRESS FACTORS AND THYMUS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(6), 188-196.
- 22. Narzulaeva, U. (2023). Pathogenetic Mechanisms of Microcirculation disorders. *International Bulletin of Medical Sciences and Clinical Research*, 3(10), 60-65.
- 23. Narzullaeva, U. R., Samieva, G. U., & Samiev, U. B. (2020). The importance of a healthy lifestyle in eliminating risk factors in the early stages of hypertension. *Journal Of Biomedicine And Practice*, 729-733.
- 24. ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY. Valeology: International Journal of Medical Anthropology and Bioethics, 2(09), 106-111.
- 25. Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune Thyroiditis. *American Journal of Bioscience and Clinical Integrity*, 1(10), 43-50.
- 26. Tolibov, F. F. (2024). The Syndrome of External Secretory Function Insufficiency is a Common Complication of Chronic Pancreatitis. *American Journal of Bioscience and Clinical Integrity*, 1(10), 90-95.
- 27. Farxodivich, T. F. (2024). Clinical Characteristics of Gastritis in Digestive Diseases. *Research Journal of Trauma and Disability Studies*, *3*(3), 152-157.
- 28. Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES. *TADQIQOTLAR. UZ*, 40(3), 55-62.
- 29. Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH COMORBID DISEASES. *TADQIQOTLAR. UZ*, 40(3), 71-77.
- 30. Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB CHIQARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI. *TADQIQOTLAR. UZ*, 40(3), 63-70.
- 31. Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI BO'LGAN BEMORLARDA GLIKEMIK NAZORAT. *TADQIQOTLAR. UZ*, *40*(3), 48-54.
- 32. Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE) IN TYPE 2 DIABETES. JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH, 3(5), 210-216.
- 33. Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(4), 171-177.

NEW RENAISSANCE international scientific journal

ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

- 35. Toxirovna, E. G. (2024). QALQONSIMON BEZ KASALLIKLARIDAN HASHIMOTO TIREODIT KASALLIGINING MORFOFUNKSIONAL O'ZIGA XOSLIGI. *Modern education and development*, *16*(7), 120-135.
- 36. Toxirovna, E. G. (2024). REVMATOID ARTRIT: BO'G'IMLAR YALLIG'LANISHINING SABABLARI, KLINIK BELGILARI, OQIBATLARI VA ZAMONAVIY DAVOLASH YONDASHUVLARI. Modern education and development, 16(7), 136-148.
- 37. Эргашева, Г. Т. (2024). ОЦЕНКА КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ ОРЛИСТАТА У БОЛЬНЫХ ОЖИРЕНИЕМ И АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. Modern education and development, 16(7), 92-105.
- 38. Эргашева, Г. Т. (2024). СНИЖЕНИЕ РИСКА ОСЛОЖНЕНИЙ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ. Образование Наука И Инновационные Идеи В Мире, 38(7), 210-218.
- 39. Tokhirovna, E. G. (2024). CLINICAL AND MORPHOLOGICAL ASPECTS OF THE COURSE OF ARTERIAL HYPERTENSION. Лучшие интеллектуальные исследования, 12(4), 234-243.
- 40. Tokhirovna, E. G. Studying the Causes of the Relationship between Type 2 Diabetes and Obesity. *Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN*, 2456-6470.
- 41. Toxirovna, E. G. (2024). ARTERIAL GIPERTENZIYA KURSINING KLINIK VA MORFOLOGIK JIHATLARI. Лучшие интеллектуальные исследования, 12(4), 244-253.
- 42. Эргашева, Г. Т. (2024). НОВЫЕ АСПЕКТЫ ТЕЧЕНИЕ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ У ВЗРОСЛОГО НАСЕЛЕНИЕ. Лучшие интеллектуальные исследования, 12(4), 224-233.
- 43. Эргашева, Г. Т. (2024). ФАКТОРЫ РИСКА РАЗВИТИЯ САХАРНОГО ДИАБЕТА 2 ТИПА. ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ, 36(5), 70-74.
- 44. Эргашева, Г. Т. (2024). ОСЛОЖНЕНИЯ САХАРНОГО ДИАБЕТА 2 ТИПА ХАРАКТЕРНЫ ДЛЯ КОГНИТИВНЫХ НАРУШЕНИЙ. *TADQIQOTLAR. UZ*, 30(3), 112-119.
- 45. Эргашева, Г. Т. (2023). Исследование Причин Связи Диабета 2 Типа И Ожирения. *Research Journal of Trauma and Disability Studies*, 2(12), 305-311.

1150

- **46.** Tokhirovna, E. G. (2024). Risk factors for developing type 2 diabetes mellitus. *OEPA3OBAHUE HAVKA И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(5), 64-69.
- 47. Шокиров, Б., & Халимова, Ю. (2021). Antibiotic-induced rat gut microbiota dysbiosis and salmonella resistance. *Общество и инновации*, 2(4/S), 93-100.
- 48. Шокиров, Б. С., & Халимова, Ю. С. (2021). Пищеварительная функция кишечника после коррекции экспериментального дисбактериоза у крыс бифидобактериями. In Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.. Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации.
- 49. Salokhiddinovna, X. Y. (2023). Anemia of Chronic Diseases. *Research Journal of Trauma and Disability Studies*, 2(12), 364-372.
- 50. Salokhiddinovna, X. Y. (2023). MALLORY WEISS SYNDROME IN DIFFUSE LIVER LESIONS. *Journal of Science in Medicine and Life*, *1*(4), 11-15.
- 51. Salohiddinovna, X. Y. (2023). SURUNKALI KASALLIKLARDA UCHRAYDIGAN ANEMIYALAR MORFO-FUNKSIONAL XUSUSIYATLARI. *Ta'lim innovatsiyasi va integratsiyasi*, 10(3), 180-188.
- 52. Халимова, Ю. С. (2024). КЛИНИКО-МОРФОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ВИТАМИНА D В ФОРМИРОВАНИЕ ПРОТИВОИНФЕКЦИОННОГО ИММУНИТА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(3), 86-94.
- 53. Saloxiddinovna, X. Y. (2024). CLINICAL FEATURES OF VITAMIN D EFFECTS ON BONE METABOLISM. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(5), 90-99.
- 54. Saloxiddinovna, X. Y. (2024). CLINICAL AND MORPHOLOGICAL ASPECTS OF AUTOIMMUNE THYROIDITIS. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(5), 100-108.
- 55. Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES BLOOD MORPHOLOGY IN AGE-RELATED CHANGES. Лучшие интеллектуальные исследования, 14(4), 146-158.

56. Saloxiddinovna, X. Y. (2024). CLINICAL MORPHOLOGICAL CRITERIA OF LEUKOCYTES. Лучшие интеллектуальные исследования, 14(4), 159-167.

NEW RENAISSANCE international scientific journal

ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 2

- 57. Saloxiddinovna, X. Y. (2024). Current Views of Vitamin D Metabolism in the Body. *Best Journal of Innovation in Science, Research and Development*, *3*(3), 235-243.
- 58. Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES OF THE STRUCTURE AND DEVELOPMENT OF THE OVARIES. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(4), 220-227.

